Wound Management Technologies (OTCMKTS:WNDM) and Sientra (NASDAQ:SIEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Institutional & Insider Ownership
87.0% of Sientra shares are held by institutional investors. 9.6% of Wound Management Technologies shares are held by insiders. Comparatively, 31.0% of Sientra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings for Wound Management Technologies and Sientra, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wound Management Technologies||0||0||0||0||N/A|
Sientra has a consensus price target of $24.14, suggesting a potential upside of 64.01%. Given Sientra’s higher possible upside, analysts clearly believe Sientra is more favorable than Wound Management Technologies.
Risk & Volatility
Wound Management Technologies has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Sientra has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500.
This table compares Wound Management Technologies and Sientra’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wound Management Technologies||1.79%||12.58%||5.17%|
Earnings and Valuation
This table compares Wound Management Technologies and Sientra’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Wound Management Technologies||$6.30 million||1.13||$330,000.00||N/A||N/A|
|Sientra||$36.54 million||11.52||-$64.02 million||($2.82)||-5.22|
Wound Management Technologies has higher earnings, but lower revenue than Sientra.
Sientra beats Wound Management Technologies on 6 of the 11 factors compared between the two stocks.
About Wound Management Technologies
WNDM Medical Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. The company offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as Wound Management Technologies, Inc. and changed its name to WNDM Medical Inc. in April 2017. WNDM Medical Inc. was founded in 1982 and is based in Fort Worth, Texas.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline-filled breast implant sizers to identify the correct style and size of implants; and non-breast tissue expanders for expanding tissue and skin surface area for burn care and other reconstructive use. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Receive News & Ratings for Wound Management Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wound Management Technologies and related companies with MarketBeat.com's FREE daily email newsletter.